sumatriptan has been researched along with Rosacea in 1 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
Rosacea: A cutaneous disorder primarily of convexities of the central part of the FACE, such as FOREHEAD; CHEEK; NOSE; and CHIN. It is characterized by FLUSHING; ERYTHEMA; EDEMA; RHINOPHYMA; papules; and ocular symptoms. It may occur at any age but typically after age 30. There are various subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular (National Rosacea Society's Expert Committee on the Classification and Staging of Rosacea, J Am Acad Dermatol 2002; 46:584-7).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We established a clinical experimental model of rosacea features and showed that sumatriptan was able to attenuate PACAP38-induced rosacea flushing and edema." | 9.41 | Infusion of Pituitary Adenylate Cyclase-Activating Polypeptide-38 in Patients with Rosacea Induces Flushing and Facial Edema that Can Be Attenuated by Sumatriptan. ( Ashina, M; Christensen, CE; Coskun, H; Egeberg, A; Ghanizada, H; Thyssen, JP; Wienholtz, NKF; Zhang, DG, 2021) |
| "We established a clinical experimental model of rosacea features and showed that sumatriptan was able to attenuate PACAP38-induced rosacea flushing and edema." | 5.41 | Infusion of Pituitary Adenylate Cyclase-Activating Polypeptide-38 in Patients with Rosacea Induces Flushing and Facial Edema that Can Be Attenuated by Sumatriptan. ( Ashina, M; Christensen, CE; Coskun, H; Egeberg, A; Ghanizada, H; Thyssen, JP; Wienholtz, NKF; Zhang, DG, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wienholtz, NKF | 1 |
| Christensen, CE | 1 |
| Coskun, H | 1 |
| Zhang, DG | 1 |
| Ghanizada, H | 1 |
| Egeberg, A | 1 |
| Thyssen, JP | 1 |
| Ashina, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigation of PACAP38-induced Headache and Rosacea-like Symptoms in Patients With Rosacea[NCT03878784] | 38 participants (Actual) | Interventional | 2018-11-12 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for sumatriptan and Rosacea
| Article | Year |
|---|---|
Infusion of Pituitary Adenylate Cyclase-Activating Polypeptide-38 in Patients with Rosacea Induces Flushing and Facial Edema that Can Be Attenuated by Sumatriptan.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Edema; Face; Female; Flushing; Humans; Infusions, In | 2021 |